Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 25, 2022

Efficacy of Pertuzumab Retreatment for HER2+ Advanced Breast Cancer

Cancer science


Additional Info

Cancer science
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS)
Cancer Sci. 2022 Sep 01;113(9)3169-3179, Y Yamamoto, H Iwata, N Taira, N Masuda, M Takahashi, T Yoshinami, T Ueno, T Toyama, T Yamanaka, T Takano, M Kashiwaba, K Tsugawa, Y Hasegawa, K Tamura, H Tada, F Hara, T Fujisawa, N Niikura, S Saji, S Morita, M Toi, S Ohno

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading